US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5932448A
· Tso et al.
· 1999
[cited by applicant]
US 6248516B1
· Winter et al.
· 2001
[cited by applicant]
US 7183076B2
· Arathoon et al.
· 2007
[cited by applicant]
US 7612041B2
· Knopf et al.
· 2009
[cited by applicant]
US 7709605B2
· Knopf et al.
· 2010
[cited by applicant]
US 7820620B2
· Vale et al.
· 2010
[cited by applicant]
US 7842663B2
· Knopf et al.
· 2010
[cited by applicant]
US 8216997B2
· Seehra et al.
· 2012
[cited by applicant]
US 8293881B2
· Seehra et al.
· 2012
[cited by applicant]
US 8592562B2
· Kannan et al.
· 2013
[cited by applicant]
US 8734760B2
· O'Connor-McCourt et al.
· 2014
[cited by applicant]
US 9611306B2
· Hinck et al.
· 2017
[cited by applicant]
US 9809638B2
· Sun et al.
· 2017
[cited by applicant]
US 20040223966A1
· Wolfman et al.
· 2004
[cited by applicant]
US 20120302737A1
· Christensen et al.
· 2012
[cited by applicant]
US 20170240639A1
· Kumar et al.
· 2017
[cited by applicant]
US 20170306027A1
· Knopf et al.
· 2017
[cited by applicant]
US 20180008672A1
· Chalothorn et al.
· 2018
[cited by applicant]
US 20180111991A1
· Miller et al.
· 2018
[cited by applicant]
CN 103221426A
· 2013
[cited by applicant]
EP 2108017A2
· 2009
[cited by applicant]
EP 3101029A1
· 2016
[cited by applicant]
JP 2016037488A
· 2016
[cited by applicant]
WO WO9311162A1
· 1993
[cited by applicant]
WO WO9411502A2
· 1994
[cited by applicant]
WO WO0043781A2
· 2000
[cited by applicant]
WO WO03093478A1
· 2003
[cited by applicant]
WO WO2004039948A2
· 2004
[cited by applicant]
WO WO2005028433A2
· 2005
[cited by applicant]
WO WO2006012627A2
· 2006
[cited by applicant]
WO WO2007147901A1
· 2007
[cited by applicant]
WO WO2008073351A2
· 2008
[cited by applicant]
WO WO2008097541A2
· 2008
[cited by applicant]
WO WO2009089004A1
· 2009
[cited by applicant]
WO WO2010019261A1
· 2010
[cited by applicant]
WO WO2010083034A1
· 2010
[cited by applicant]
WO WO2010151426A1
· 2010
[cited by applicant]
WO WO2011034605A2
· 2011
[cited by applicant]
WO WO2011045497A1
· 2011
[cited by applicant]
WO WO2011117329A1
· 2011
[cited by applicant]
WO WO2012088302A2
· 2012
[cited by applicant]
WO WO2013000234A1
· 2013
[cited by applicant]
WO WO2016154601A1
· 2016
[cited by applicant]
WO WO2016164497A1
· 2016
[cited by applicant]
WO WO2016205370A1
· 2016
[cited by applicant]
WO WO2017037634A1
· 2017
[cited by applicant]
WO WO2018009624A1
· 2018
[cited by applicant]
WO WO2018075747A1
· 2018
[cited by applicant]
Agapova et al., Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney International 89, 1231-1243, 2016.
[cited by examiner]
Kumar et al., Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily. Nature, Scientifc Reports, 11:18341, 2021.
[cited by examiner]
Allendorph, et al., “Structure of the ternary signaling complex of a TGF-β superfamily member,” Proceedings of the National Academy of Sciences, vol. 103(20): 7643-7648 (2006).
[cited by applicant]
Andersson et al., “Growth differentiation factor 11 signals through the transforming growth factor-β receptor ALK5 to regionalize the anterior-posterior axis,” EMBO Reports, vol. 7(8): 831-837 (2006).
[cited by applicant]
Armes et al., “A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development,”, The Journal of Biological Chemistry: 7929 (19…
[cited by applicant]
Ashmore, et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and “Double-Muscled” Cattle,” Growth, vol. 38: 501-506 (1974).
[cited by applicant]
Attie et al., “A phase I study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers,” American Journal of Hematology, vol. 89(7): 766-770 (2014).
[cited by applicant]
Attisano, et al., “Novel Activin Receptors: Distinct Genes and Alternative mRNA Splicing Generate a Repertoire of Serine/Threonine Kinase Receptors,” Cell, vol. 68: 97-108 (1992).
[cited by applicant]
Bianco et al., “Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial cells,” Molecular and Cellular Biology, American Society for Pharmacology and Experimental Therapeut…
[cited by applicant]
Bogdanovich, et al., “Functional improvement of dystrophic muscle by myostatin blockade,” Nature, vol. 420: 418-421 (2002).
[cited by applicant]
Brown, et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3,” Growth Factors, vol. 3: 35-43 (1990).
[cited by applicant]
Calvanese, et al., “Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor,” Journal of Peptide Science, vol. 15: 175-183 (2009).
[cited by applicant]
Calvanese et al., “Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments: Conformational and binding properties of Nodal synthetic fragments”, Journal of Peptide Science, v…
[cited by applicant]
Cantini, et al., “Profibrotic Role of Myostatin in Peyronie's Disease,” Journal of Sexual Medicine, vol. 5: 1607-1622 (2008).
[cited by applicant]
Chiu et al., “Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents,” The Journals of Gerontology: Biological Sciences. vol. 68(10): 1181-1192 (2013).
[cited by applicant]
Clouthier, et al., “Hepatic Fibrosis, Glomerulosclerosis, and a Lipodystrophy-like Syndrome in PEPCK-TGF-β1 Transgenic Mice,” Journal of Clinical Investigation, vol. 100(11): 2697-2713 (1997).
[cited by applicant]
Das, et al., “Macromolecular Modeling with Rosetta,” Annual Review of Biochemistry, vol. 77: 363-382 (2008).
[cited by applicant]
Davis, et al., “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies,” Protein Engin…
[cited by applicant]
DePaolo, et al., “Follistatin and Activin: A Potential Intrinsic Regulatory System with Diverse Tissues,” Proceedings of the Society for Experimental Biology and Medicine: 500-512 (1991).
[cited by applicant]
Dyson, et al., “Activin signalling has a necessary function in Xenopus early development,” Current Biology, vol. 7(1): 81-84 (1997).
[cited by applicant]
Fenn, et al., “Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain,” PLoS ONE, vol. 8(4): e61953 (2013).
[cited by applicant]
Gamer, et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer in Xenopus Embryos,” Developmental Biology, vol. 208: 222-232 (1999).
[cited by applicant]
Gamer, et al., “Gdf11 Is a Negative Regulator of Chrondrogenesis and Myogenesis in the Developing Chick Limb,” Developmental Biology, vol. 229: 407-420 (2001).
[cited by applicant]
Gonzalez-Cadavid, et al., “Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting,” Proceedings of the National Academy of Sciences, vol. 95: 14938-14943 (1998).
[cited by applicant]
Goumans, et al., “Activin Receptor-like Kinase (ALK)1 Is an Antagonistic Mediator of Lateral TGFβ/ALK5 Signaling,” Molecular Cell, vol. 12: 817-828 (2003).
[cited by applicant]
Greenwald, et al., “Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase,” Nature Structural Biology, vol. 6(1): 18-22 (1999).
[cited by applicant]
Grobet, et al., “A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle,” Nature Genetics, vol. 17: 71-74 (1997).
[cited by applicant]
Gunasekaran, et al., “Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects,” The Journal of Biological Chemistry, vol. 285(25): 19637-19646 (2010).
[cited by applicant]
Hao et al., “Elevation of Expression of Smads 2, 3, and 4, Decorin and TGF-Beta in the Chronic Phase of Myocardial Infarct Scar Healing,” Journal of Mol. Cell. Cardiol., vol. 31(3): 667-678 (1999).
[cited by applicant]
Hardy, et al., “The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology,” Immunology and Cell Biology, vol. 93: 567-574 (2015).
[cited by applicant]
Harrison, et al., “Identification of a Functional Binding Site for Activin on the Type I Receptor ALK4,” The Journal of Biological Chemistry, vol. 278: 21129-21135 (2003).
[cited by applicant]
Hedger, et al., “The activins and their binding protein, follistatin—Diagnostic and therapeutic targets in inflammatory disease and fibrosis,” Cytokine & Growth Factor Reviews, vol. 24: 285-295 (2013).
[cited by applicant]
Hildén, et al., “Expression of Type II Activin Receptor Genes During Differentiation of Human K562 Cells and cDNA Cloning of the Human Type IIB Activin Receptor,” Blood, vol. 83(8): 2163-2170 (1994).
[cited by applicant]
Hinck, “Structural studies of the TGF-βs and their receptors—insights into evolution of the TGF-β superfamily,” Federation of European Biochemical Societies Letters, vol. 586: 1860-1870 (2012).
[cited by applicant]
Kabat, et al., “Sequences of Proteins of Immunological Interest,” Fifth Edition, Public Health Service National Institutes of Health, NIH Publication No. 91-3242: 688-696 (1991).
[cited by applicant]
Kambadur, et al., “Mutations in myostatin (GDF8) in Double-Muscled Belgian Blue and Piedmontese Cattle,” Genome Research, vol. 7: 910-915 (1997).
[cited by applicant]
Klahr, et al., “Obstructive nephropathy and renal fibrosis,” American Journal of Physiology—Renal Physiology, vol. 283: F861-F875 (2002).
[cited by applicant]
Klein, et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs, vol. 4(6): 653-663 (2012).
[cited by applicant]
Koncarevic et al., “A Soluble Activin Receptor Type IIB Prevents the Effects of Angdrogen Deprivation on Body Composition and Bone Health,” Endocrinology, vol. 151(9): 4289-4300 (2010).
[cited by applicant]
Kubiczkova, et al., “TGF-β—an excellent servant but a bad master,” Journal of Translational Medicine, vol. 10(183): 24 pages (2012).
[cited by applicant]
Lei et al., Effect of Efonidipine on TGF-Berta1-Induced Cardiac Fiborsis Through Smad2-Dependent Pathway in Rat Cardiac Fibroblasts, Journal of Pharmacol. Sci., vol. 117(2): 98-105 (2011).
[cited by applicant]
Lewis, et al., “Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface,” Nature Biotechnology, vol. 32(2): 191-198 (2014).
[cited by applicant]
Li, et al., “Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms,” Immunity, vol. 25: 455-471 (2006).
[cited by applicant]
Lin, et al., “The structural basis of TGF-β, bone morphogenetic protein, and activin ligand binding,” Reproduction, vol. 132: 179-190 (2006).
[cited by applicant]
Macías-Silva, et al., “Specific Activation of Smad1 Signaling Pathways by the BMP7 Type I Receptor, ALK2*,” The Journal of Biological Chemistry, vol. 273(40): 25628-25636 (1998).
[cited by applicant]
Maeshima et al., “Follistatin, an Activin Antagonist, Ameliorates Renal Interstitial Fibrosis in a Rat Model of Unilateral Obstruction,” BioMed Research International, vol. 2014: 1-13 (2014).
[cited by applicant]
Massagué, “How Cells Read TGF-β Signals,” Nature Reviews Molecular Cell Biology, vol. 1(3): 169-178 (2000).
[cited by applicant]
McPherron, et al., “Double muscling in cattle due to mutations in the myostatin gene,” Proceedings of the National Academy of Sciences, vol. 94: 12457-12461 (1997).
[cited by applicant]
McPherron, et al., “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,” Nature, vol. 387: 83-90 (1997).
[cited by applicant]
McPherron, et al., “Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11,” Nature Genetics, vol. 22: 260-264 (1999).
[cited by applicant]
Meng et al., “TGF-Beta/Smad Signaling in Renal Fibrosis,” Frontier in Physiology, vol. 6, Article 82: 1-8 (2015).
[cited by applicant]
Merchant, et al., “An efficient route to human bispecific IgG,” Nature Biotechnology, vol. 16: 677-681 (1998).
[cited by applicant]
Miyazono, et al., “Latent High Molecular Weight Complex of Transforming Growth Factor β1,” The Journal of Biological Chemistry, vol. 263(13): 6407-6415 (1998).
[cited by applicant]
Nakashima, et al., “Expression of growth/differentiation factor 11, a new member of the BMP/TGFβ superfamily during mouse embryogenesis,” Mechanisms of Development, vol. 80: 185-189 (1999).
[cited by applicant]
Pack, et al., “Miniantibodies: Use of Amphipathic Helices to Produce Functional, Flexibly Linked Dimeric Fv Fragments with High Avidity in
[cited by applicant]
Pack, et al., “Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of
[cited by applicant]
Pistilli, et al., “Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy,” The American Journal of Pathology, vol. 178(3): 1287-1297 (2011).
[cited by applicant]
Qin et al., “A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands,” Oncotarget, Advance Publications: 1-16 (2016).
[cited by applicant]
Recombinant Human Activin A Receptor, Type 1B (ACVR1B), GIBCO, Publication Part No. MAN0004539, Jun. 16, 2011, 2 pages, downloaded Nov. 6, 2017.
[cited by applicant]
Rider, et al., “Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists,” Biochemical Journal, vol. 429: 1-12 (2010).
[cited by applicant]
Ridgway, et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Engineering, vol. 19(7): 617-621 (1996).
[cited by applicant]
Romano, et al., “Toward a better understanding of the interaction between TGF-β family members and their ALK receptors,” Journal of Molecular Modeling, vol. 18: 3617-3625 (2012).
[cited by applicant]
Sako, D., et al., “Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB,” The Journal of Biological Chemistry, 285(27):21037-21048 (2010).
[cited by applicant]
Sakuma, et al., “Inhibition of Nodal signalling by Lefty mediated through interaction with common receptors and efficient diffusion,” Genes to Cells, vol. 7: 401-412 (2002).
[cited by applicant]
Schaefer et al., “Immunoglobulin domain crossover as a genetic approach for the production of bispecific IgG antibodies,” Proceedings of the National Academy of Sciences, vol. 108(27): 11187-11192 (2011).
[cited by applicant]
Schuelke, et al., “Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child,” The New England Journal of Medicine, vol. 350(26): 2682-2688 (2004).
[cited by applicant]
Shen, Michael M., “Decrypting the role of Cripto in tumorigenesis,” vol. 112(4): 500-502 (2003).
[cited by applicant]
Spiess, et al., “Alternative molecular formats and therapeutic applications for bispecific antibodies,” Molecular Immunology, vol. 67: 95-106 (2015).
[cited by applicant]
Supplementary EP Search Report (EP 17 85 9224) dated Sep. 25, 2020 (10 pages).
[cited by applicant]
Swatland, et al., “Fetal Development of the Double Muscled Condition in Cattle,” Journal of Animal Science, vol. 38(4): 752-757 (1974).
[cited by applicant]
Thompson, et al., “Structures of an ActRIIB: activin A complex reveal a novel binding mode for TGF-β ligand: receptor interactions,” The EMBO Journal, vol. 22(7): 1555-1566 (2003).
[cited by applicant]
Tsuchida et al., “Activin signaling as an emering target for therapeutic interventions,” Cell Communication and Signaling: vol. 7(15) (2009). (11 pages).
[cited by applicant]
Tsuchida et al., “Signal Transduction Pathway through Activin Receptors as a Therapeutic Target of Musculoskeletal Diseases and Cancer,” Endocrine Journal, vol. 55(1): 11-21 (2008).
[cited by applicant]
Wakefield, et al., “Latent Transforming Growth Factor-β from Human Platelets,” The Journal of Biological Chemistry, vol. 263(16): 7646-7654 (1988).
[cited by applicant]
Weiss, et al., “The TGFbeta Superfamily Signaling Pathway,” Developmental Biology, vol. 2: 47-63 (2013).
[cited by applicant]
Woodruff, “Regulation of Cellular and System Function by Activin,” Biochemical Pharmacology, vol. 55: 953-963 (1998).
[cited by applicant]
Wranik, et al., “LUZ-Y, a Novel Platform for the Mammalian Cell Production of Full-length IgG-bispecific Antibodies,” The Journal of Biological Chemistry, vol. 287(52): 43331-43339 (2012).
[cited by applicant]
Wu, et al., “Autoregulation of Neurogenesis by GDF11,” Neuron, vol. 37: 197-207 (2003).
[cited by applicant]
Zhou et al., “Truncated Activin Type I Receptor Alk4 Isoforms are Dominant Negative Receptors Inhibiting Activin Signaling,” Molecular Endocrinology, vol. 14(12): 2066-2075 (2000).
[cited by applicant]
Zhu et al., “Inhibin alpha-subunit N-terminal Extension Interacts with ALK4 and Disrupts the Activin/ActRIIB/ALK4 Complex”, Biology of Reproduction, vol. 83, Issue Suppl_1: p. 194 (2010) (only abstract published).
[cited by applicant]
Zhu et al., “Inhibin alpha-Subunit N Terminus Interacts with Activin Type IB Receptor to Disrupt Activin Signaling”, The Journal of Biological Chemistry, vol. 287(11): 8060-8070 (2012).
[cited by applicant]
Zimmers, et al., “Induction of Cachexia in Mice by Systemically Administered Myostatin,” Science, vol. 296: 1486-1488 (2002).
[cited by applicant]
Zwaagstra et al., “Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps,” Molecular Cancer Therapeutics; vol. 11(7): 1477-1487 (2012).
[cited by applicant]
Huang, Chichi, “Receptor-Fc fusion therapeutics, traps and MIMETIBODYTM technology”, ScienceDirect, Current Opinion in Biotechnology, vol. 20: 692-699 (2009).
[cited by applicant]
Issued U.S. Pat. No. 10,196,434 (U.S. Appl. No. 15/092,573).
[cited by applicant]
Issued U.S. Pat. No. 10,738,098 (U.S. Appl. No. 16/158,661).
[cited by applicant]
Abandoned U.S. Appl. No. 16/354,709.
[cited by applicant]
Issued U.S. Pat. No. 11,279,746 (U.S. Appl. No. 16/803,230).
[cited by applicant]
Issued U.S. Pat. No. 10,934,532, (U.S. Appl. No. 15/726,255.
[cited by applicant]
Pending U.S. Appl. No. 17/134,703.
[cited by applicant]